Ras

Cat. No.

A19041

CAS No.

2241719-75-3

KRAS G12C inhibitor 13

KRAS G12C inhibitor 13 is a KRAS G12C inhibitor extracted from patent WO2018143315A1, compound 30.

Cat. No.

A19890

CAS No.

302826-61-5

EPAC 5376753

EPAC 5376753 is an allosterically inhibitor of Epac which inhibits Epac1 with an IC50 of 4 µM in Swiss 3T3 cells.

Cat. No.

A20875

CAS No.

84783-01-7

K-Ras-IN-1

K-Ras-IN-1 is a K-Ras inhibitor, by binding to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure.(the detailed information refer to the reference).

Cat. No.

A20931

CAS No.

1629268-19-4

K-Ras G12C-IN-3

K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

Cat. No.

A20936

CAS No.

1629267-75-9

K-Ras G12C-IN-2

K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.

Cat. No.

A20937

CAS No.

1629265-17-3

K-Ras G12C-IN-1

K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

Cat. No.

A21358

CAS No.

1593478-56-8

(R)-CE3F4

(R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1), with an IC50 of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC50, 44 μM).

Cat. No.

A21504

CAS No.

1173671-63-0

Rhosin

Rhosin is a potent, specific RhoA subfamily Rho GTPases inhibitor, which specifically binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin induces cell apoptosis.

Cat. No.

A21560

CAS No.

314042-01-8

CID-1067700

Synonyms: ML282

CID-1067700 (ML282) is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki of 13 nM.

Cat. No.

A21632

CAS No.

429653-73-6

Y16

Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM.

Cat. No.

A21648

CAS No.

1281870-42-5

Rhosin hydrochloride

Rhosin hydrochloride is a potent, specific RhoA subfamily Rho GTPases inhibitor.

Cat. No.

A21689

CAS No.

77658-84-5

(Rac)-Antineoplaston A10

(rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

Cat. No.

A22098

CAS No.

362503-73-9

RBC10

RBC10 is an inhibitor of Ral binding to RALBP1 (the effector).

Cat. No.

A22285

CAS No.

16616-39-0

MLS000532223

MLS000532223 is a high affinity, selective inhibitor of Rho family GTPases, with EC50 values ranging from 16 μM to 120 μM.

Cat. No.

A22348

CAS No.

1922098-69-8

CCG-222740

CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression.

Cat. No.

A22500

CAS No.

13728-56-8

NSC-92828

Synonyms: 3-Phenanthrenebutyric acid

NSC-92828, also known as 3-Phenanthrenebutyric acid, is a Protein-protein interaction inhibitor (PP inhibitor or PPI).

Cat. No.

A22566

CAS No.

2436544-27-1

ARS-1323-Alkyne

ARS-1323-Alkyne is a novel KRASG12C occupancy probe.

Cat. No.

A24110

CAS No.

2676177-63-0

LUNA18 (Paluratide)

Synonyms: Paluratide

LUNA18 is an orally bioavailable cyclic peptide that functions as a dual inhibitor of KRAS and ERK signaling pathways. It disrupts the interaction between RAS and guanine nucleotide exchange factors (GEFs), effectively inhibiting RAS activation and downstream signaling. In RAS-mutated cancer cells, LUNA18 reduces cell proliferation while modulating key signaling nodes, including phosphorylation of ERK and AKT. In preclinical studies, LUNA18 demonstrates potent anticancer activity, particularly in xenograft models, by blocking RAS-driven tumor growth. It shows significant cellular efficacy against cancer cell lines harboring KRAS mutations, including colon, gastric, pancreatic, and non-small cell lung cancers, highlighting its therapeutic potential as a targeted agent for RAS-driven malignancies.

Cat. No.

A24117

CAS No.

2641998-63-0

Elironrasib (RMC-6291)

Synonyms: RMC-6291

Elironrasib is an orally active, covalent inhibitor specifically targeting the active GTP-bound form of KRAS^G12C (KRAS^G12C(ON)). It uniquely functions by forming a stable tri-complex with KRAS^G12C(ON) and cyclophilin A (CypA) within tumor cells, leading to steric hindrance that blocks the interaction between KRAS and its downstream effectors. This mechanism effectively suppresses RAS-mediated signaling, particularly the ERK pathway. Elironrasib induces apoptosis in KRAS^G12C-mutant H358 non-small cell lung cancer cells and demonstrates potent antiproliferative activity across KRAS^G12C-mutant cell lines, with a median IC₅₀ of 0.11 nM. Its high specificity and novel mechanism make it a promising therapeutic candidate for cancers driven by KRAS^G12C mutations.

Cat. No.

A24118

CAS No.

2765082-12-8

RMC-7977

RMC-7977 is an orally bioavailable, triple-complex RAS inhibitor that functions by simultaneously binding to cyclophilin A (CypA; K_d = 195 nM) and KRAS^G12V (K_d = 292 μM), facilitating the formation of a stable inhibitory complex. It exhibits broad-spectrum activity against RAS isoforms—including KRAS, NRAS, and HRAS—across both wild-type and mutant variants. RMC-7977 suppresses key oncogenic signaling pathways by inhibiting the phosphorylation of ERK, CRAF, and RSK, while promoting apoptosis through enhanced PARP cleavage. This dual mechanism results in significant tumor regression and reduced acquired resistance in KRAS^G12C-driven cancer models. It also shows favorable tolerability across a range of RAS-mutant tumor models, positioning it as a promising therapeutic candidate for RAS-driven malignancies.

Cat. No.

A24187

CAS No.

2642037-07-6

RMC-4998

RMC-4998 is an orally active inhibitor that selectively targets the active, GTP-bound state of the KRAS^G12C mutant. It forms a ternary complex with intracellular cyclophilin A (CYPA) and activated KRAS^G12C, exhibiting an IC50 of 28 nM. RMC-4998 suppresses ERK signaling and induces apoptosis in KRAS^G12C-mutant cancer cells, making it a valuable candidate for tumor research.

Cat. No.

A24221

CAS No.

2771246-13-8

Olomorasib (KRAS G12C inhibitor 19)

Synonyms: KRAS G12C inhibitor 19

Olomorasib is a potent and selective inhibitor of KRAS^G12C, demonstrating significant tumor growth inhibition, as reported in patent WO2021118877A1. It is under investigation for targeted therapy in KRAS^G12C-mutant cancers

Cat. No.

A24224

CAS No.

2922732-54-3

Zoldonrasib (RMC-9805)

Synonyms: KRAS G12D inhibitor 18; RMC-9805

Zoldonrasib (RMC-9805) is a potent, orally active inhibitor selectively targeting KRAS^G12D. It induces apoptosis in KRAS^G12D-mutant cancer cells and holds significant potential for the study and treatment of KRAS^G12D-driven malignancies.

Cat. No.

A24226

CAS No.

2657613-87-9

Glecirasib (JAB-21822)

Synonyms: JAB-21822

Glecirasib (Compound 1-2; JAB-21822) is a potent and orally active inhibitor of KRAS^G12C. As a member of the Ras protein family—key regulators of intracellular signaling involved in cell growth and development—KRAS^G12C is a critical oncogenic driver. Glecirasib shows strong potential for the study and treatment of KRAS^G12C-mediated cancers.

Cat. No.

A24227

CAS No.

2794934-49-7

RGT-018

RGT-018 is a potent, orally active SOS1 inhibitor that exhibits anti-tumor activity by blocking KRAS activation. By disrupting the SOS1–KRAS interaction, RGT-018 effectively inhibits cancer cell proliferation, making it a promising candidate for targeting KRAS-driven malignancies.